Type 1 diabetes has been prevented and cured in more than 500 ways in mice, but never in humans. nPOD researchers are trying to change that, one donated organ at a time.
Research
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
61 readers recommended
Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!
42 readers recommended
Views on FDA regulation, pipeline updates, and first vs. next-generation systems.
44 readers recommended
Significant Improvement in A1c and time-in-range when adding CGM.
33 readers recommended
How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?
27 readers recommended
AADE’s Dr. Susan Guzman and diaTribe ’s Adam Brown discuss how common stigma is, why it matters, and tips to overcome it
22 readers recommended
New study shows that beta cell fragility may contribute to the risk of both type 1 and type 2 diabetes.
73 readers recommended
less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide
26 readers recommended
How close is the UN to achieving its goal of “halting the rise in diabetes and obesity” by 2025?
46 readers recommended
No fingersticks needed? Plus, a look at the “thinnest CGM ever” from Dexcom and Verily
29 readers recommended
Making major improvements over current standard of care – how does this new treatment work? The FDA recently approved a new indication for a product that has been used...
33 readers recommended
JDRF and Helmsley Charitable Trust workshop highlights future goals and expectations for glucose-responsive insulin.
38 readers recommended
People with type 2 diabetes should contact their physicians if they notice new pain, sores, or infections on their legs or feet.
47 readers recommended
LEADER results announced at #2016ADA – compared to placebo, Victoza reduces risk of cardiovascular death by 22%, plus a 22% reduction in kidney disease. More results...
70 readers recommended
The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?
45 readers recommended
Research reveals improved A1c and weight loss benefits for people with type 1 diabetes on sotagliflozin, but a slightly increased risk of DKA
38 readers recommended
FDA Approves New GLP-1 Label on Victoza to show that the medicine makes hearts healthier!
49 readers recommended
A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide
41 readers recommended
Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA
35 readers recommended
Results from the type 2 diabetes group in Dexcom’s DIaMonD trial show A1c and time-in-range benefits